This was supported by semiquantitative RT-PCR analysis of PIK3CA, AKT1, FRAP1, and RPS6KB1 genes in RB samples, suggesting that the potential therapeutic use of known inhibitors of this pathway (Chakraborty et al., 2007). This evidence concerns the gene AKT1 and retinoblastoma.